These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 27321385)

  • 1. Comparative effects of vildagliptin and sitagliptin determined by continuous glucose monitoring in patients with type 2 diabetes mellitus.
    Koyanagawa N; Miyoshi H; Ono K; Nakamura A; Cho KY; Yamamoto K; Takano Y; Dan-Noura M; Atsumi T
    Endocr J; 2016 Aug; 63(8):747-53. PubMed ID: 27321385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of 50 mg vildagliptin twice daily vs. 50 mg sitagliptin once daily on blood glucose fluctuations evaluated by long-term self-monitoring of blood glucose.
    Nomoto H; Kimachi K; Miyoshi H; Kameda H; Cho KY; Nakamura A; Nagai S; Kondo T; Atsumi T
    Endocr J; 2017 Apr; 64(4):417-424. PubMed ID: 28260702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition.
    Rizzo MR; Barbieri M; Marfella R; Paolisso G
    Diabetes Care; 2012 Oct; 35(10):2076-82. PubMed ID: 22688551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study).
    Sakamoto M; Nishimura R; Irako T; Tsujino D; Ando K; Utsunomiya K
    Cardiovasc Diabetol; 2012 Aug; 11():92. PubMed ID: 22867630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study.
    Guerci B; Monnier L; Serusclat P; Petit C; Valensi P; Huet D; Raccah D; Colette C; Quéré S; Dejager S
    Diabetes Metab; 2012 Oct; 38(4):359-66. PubMed ID: 22809630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of vildagliptin and sitagliptin in lowering fasting plasma glucose: Results of a randomized controlled trial.
    Göke R; Eschenbach P; Dütting ED
    Diabetes Metab; 2015 Jun; 41(3):244-7. PubMed ID: 25457473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials.
    Signorovitch JE; Wu EQ; Swallow E; Kantor E; Fan L; Gruenberger JB
    Clin Drug Investig; 2011; 31(9):665-74. PubMed ID: 21819162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations.
    Marfella R; Barbieri M; Grella R; Rizzo MR; Nicoletti GF; Paolisso G
    J Diabetes Complications; 2010; 24(2):79-83. PubMed ID: 19261490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Acarbose on Glycemic Variability in Patients with Poorly Controlled Type 2 Diabetes Mellitus Receiving Stable Background Therapy: A Placebo-Controlled Trial.
    Derosa G; Franzetti I; Querci F; D'Angelo A; Maffioli P
    Pharmacotherapy; 2015 Nov; 35(11):983-90. PubMed ID: 26598090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment.
    Baranov O; Kahle M; Deacon CF; Holst JJ; Nauck MA
    Diabetes Obes Metab; 2016 Nov; 18(11):1100-1109. PubMed ID: 27300579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of dipeptidyl peptidase-4 inhibitors on serum adiponectin: a meta-analysis.
    Liu X; Men P; Wang Y; Zhai S; Liu G
    Lipids Health Dis; 2016 Nov; 15(1):204. PubMed ID: 27881129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial.
    Kothny W; Lukashevich V; Foley JE; Rendell MS; Schweizer A
    Diabetologia; 2015 Sep; 58(9):2020-6. PubMed ID: 26067186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormonal and metabolic effects of morning or evening dosing of the dipeptidyl peptidase IV inhibitor vildagliptin in patients with type 2 diabetes.
    He YL; Valencia J; Zhang Y; Schwartz SL; Ligueros-Saylan M; Foley J; Dole WP
    Br J Clin Pharmacol; 2010 Jul; 70(1):34-42. PubMed ID: 20642545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dipeptidyl peptidase-4 inhibitor (vildagliptin) improves glycemic control after meal tolerance test by suppressing glucagon release.
    Okamoto A; Yokokawa H; Sanada H
    Drugs R D; 2014 Dec; 14(4):227-32. PubMed ID: 25204760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative analysis of the effects of alogliptin and vildagliptin on glucose metabolism in type 2 diabetes mellitus.
    Tanaka K; Okada Y; Mori H; Miyazaki M; Kuno F; Sonoda S; Sugai K; Hajime M; Kurozumi A; Narisawa M; Torimoto K; Arao T; Mine S; Tanaka Y
    Endocr J; 2017 Feb; 64(2):179-189. PubMed ID: 27840383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus.
    Richter B; Bandeira-Echtler E; Bergerhoff K; Lerch CL
    Cochrane Database Syst Rev; 2008 Apr; 2008(2):CD006739. PubMed ID: 18425967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of vildagliptin versus sitagliptin, on cardiac function, heart rate variability and mitochondrial function in obese insulin-resistant rats.
    Apaijai N; Pintana H; Chattipakorn SC; Chattipakorn N
    Br J Pharmacol; 2013 Jul; 169(5):1048-57. PubMed ID: 23488656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes.
    Ahrén B; Pacini G; Tura A; Foley JE; Schweizer A
    Horm Metab Res; 2007 Nov; 39(11):826-9. PubMed ID: 17992639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in body weight after 24 weeks of vildagliptin therapy as a function of fasting glucose levels in patients with type 2 diabetes.
    Blüher M; Schweizer A; Bader G; Foley JE
    Vasc Health Risk Manag; 2014; 10():661-4. PubMed ID: 25429228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Glycemic Control on Chylomicron Metabolism and Correlation between Postprandial Metabolism of Plasma Glucose and Chylomicron in Patients with Type 2 Diabetes Treated with Basal-bolus Insulin Therapy with or without Vildagliptin.
    Okajima F; Emoto N; Kato K; Sugihara H
    J Atheroscler Thromb; 2017 Feb; 24(2):157-168. PubMed ID: 27397060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.